Inhaler Therapy for Chronic Bronchitis

Initial Treatment Approach

The American Thoracic Society recommends starting with a short-acting bronchodilator (SABA or SAMA) for intermittent symptoms in patients with low symptoms and low exacerbation risk 1, 3
For patients with persistent symptoms, the American College of Chest Physicians recommends using a long-acting bronchodilator (LABA or LAMA) 1, 4
The American Thoracic Society suggests continuing, stopping, or trying an alternative class of bronchodilator based on symptomatic response 2

For patients with high symptoms and low exacerbation risk, the American College of Chest Physicians recommends initial therapy with a long-acting bronchodilator (LABA or LAMA) 1, 3
The American Thoracic Society recommends escalating to LABA/LAMA combination therapy for persistent breathlessness on monotherapy 1, 4
For patients with severe breathlessness, the American College of Chest Physicians suggests considering initial therapy with dual bronchodilators (LABA/LAMA) 1

For patients with chronic bronchitis phenotype and frequent exacerbations, the European Respiratory Society recommends considering LAMA or ICS+LABA as initial therapy 5, 6
The American Thoracic Society suggests adding roflumilast for persistent exacerbations with severe airflow obstruction 1, 3
For patients with severe to very severe airflow obstruction and frequent exacerbations despite optimal inhaler therapy, the American College of Chest Physicians recommends considering adding a macrolide (in former smokers) 1, 2

The American Thoracic Society recommends against long-term monotherapy with ICS alone for chronic bronchitis 1, 7
The American College of Chest Physicians emphasizes the importance of regular reassessment of response to therapy, with adjustment based on symptom control and exacerbation frequency 1, 3
The American Thoracic Society highlights the need for careful consideration of inhaler technique and device selection based on patient ability to use the device properly 3

The American College of Chest Physicians warns against overuse of ICS in patients without frequent exacerbations or asthma features 1, 4
The American Thoracic Society cautions against failure to escalate therapy in patients with persistent symptoms or exacerbations 1, 3
The American College of Chest Physicians recommends considering comorbidities that may influence treatment choices 8
The American Thoracic Society stresses the importance of adequate attention to inhaler technique, which can significantly impact medication effectiveness 3